Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A rare and sometimes fatal
metabolic bone disease .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word hypophosphatasia.
Examples
-
Enobia's lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs.
Alexion to Acquire Enobia Pharma for Up to $1.08 Billion Tess Stynes 2011
-
ENB-0040, an investigational treatment for hypophosphatasia, is a subcutaneous enzyme replacement therapy of tissue non-specific alkaline phosphatase (TNSALP) fused to a patented bone targeting peptide.
-
MONTREAL, March 29/PRNewswire/-- Enobia Pharma Inc. unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting.
-
Enobia Pharma Inc. unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010
THE MEDICAL NEWS Editors 2010
-
ENB-0040, an investigational drug for the treatment of hypophosphatasia, is the Company's lead program.
-
Enzyme Replacement Therapy for the treatment of hypophosphatasia is the Company's lead program.
-
Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced completion of target enrollment in its pilot clinical trial in infants suffering from a severe form of hypophosphatasia.
-
MONTREAL, March 03, 2009 / PRNewswire / -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced completion of target enrollment in its pilot clinical trial in infants suffering from a severe form of hypophosphatasia.
unknown title 2009
-
ENB-002-08 is an open-label, six month study evaluating safety, efficacy and pharmacokinetics of subcutaneous ENB-0040 in hypophosphatasia infants with severe rickets and respiratory compromise.
-
A Phase I study, which evaluated safety, tolerability and pharmacokinetics of ENB-0040 in adults with hypophosphatasia was completed in December of 2008.
-
Dawn Patterson relies on the Boilermakers National Health and Welfare Fund to cover the bulk of the cost of her prescription of Strensiq for treating hypophosphatasia, a rare genetic bone disease believed to affect just 1,300 people in the United States.
The Weekly | Life-Changing Drugs Almost Nobody Can Afford 2021
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.